5:52 PM
 | 
Mar 03, 2009
 |  BC Extra  |  Clinical News

Marinus' ganaxolone meets Phase II endpoint

Marinus (Branford, Conn.) said top-line data from a Phase IIa trial showed that ganaxolone as an adjunctive...

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >